Study Details
Full Title
A Phase 4, Randomized, Double-Blind, Third-Party Unblinded Study To Investigate The Safety And Tolerability Of BNT162b2 Rna-Based Variant-Adapted Vaccine Candidate Against SARs-Cov-2 And Evaluate The Circulating SARs-Cov-2 Spike Protein Level In Healthy Participants 18 Through 64 Years Of Age study
Principal Investigator
Emmanuel
Walter
Protocol Number
PRO00120065
Phase
IV
Enrollment Status
Open to Enrollment